Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17019678 | 0.92 | SMN1; SMN2 (0.36) | CA1CA2CA7CA9BRD4 | |
| SCHEMBL17019572 | 0.92 | PDE7A (0.33) | CA1CA2CA7CA9BRD4 | |
| SCHEMBL18870236 | 0.91 | PDE7A (0.38) | MAPTPDE7ASMN1; SMN2 | |
| SCHEMBL17019703 | 0.88 | MAPT (0.33) | MAPTPDE7A | |
| SCHEMBL17019675 | 0.86 | CYP1A2 (0.40) | OPRM1 | |
| SCHEMBL17019570 | 0.83 | BRD4 (0.32) | BRD4 | |
| SCHEMBL9056340 | 0.78 | KDM4E (0.36) | CA1CA2CA7CA9BRD4 | |
| SCHEMBL17014263 | 0.68 | — | — | |
| SCHEMBL15747124 | 0.68 | SMN1; SMN2 (0.34) | CA1CA2CA7CA9SMN1; SMN2 | |
| SCHEMBL20434229 | 0.63 | UCHL1 (0.39) | CA1CA2CA7CA9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900656-B1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | HAVCR2, SLC10A1, SORD | CA1 2532/4885CA2 2933/4885CA7 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.